Research led by the Department of Pathology at Stanford University, California, has found that chimeric antigen receptor T (CAR T) cell therapy can potentially result in a reactivation of human herpesvirus 6 (HHV-6) by CAR T cells in patients.
Research led by the Department of Pathology at Stanford University, California, has found that chimeric antigen receptor T (CAR T) cell therapy can potentially result in a reactivation of human herpesvirus 6 (HHV-6) by CAR T cells in patients.
Leave A Comment